科技配消费,越配越对味(共16份)
科技行业辅助消费崛起
-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例:科医人,复星医药,奇致激光,半岛医疗
伴随着医美市场规模的持续扩大,中国医美器械行业发展前景可期。数据显示,预计2021年中国医美器械市场规模将超过500亿元,同比增长27.8%。从细分赛道来看,近年来,微创和无创已逐渐成为医疗美容的趋势,这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看,中国正规医美机构设备的市场份额80%是进口品牌,且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面,国家及地方先后出台政策鼓励本土医美器械品牌的发展,同时,国有品牌也通过加大自主研发投入和投资并购来扩大市场份额,未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒报告|2019-2020中国乳业行业运行大数据及市场趋势研究报告
本报告研究涉及企业/品牌/案例:伊利集团、蒙牛集团、飞鹤乳业、光明乳业;其他提及企业/品牌:Vinamilk、TH True Milk、Moc Chau Milk、NutiFood、Hanoimilk、澳优、健合集团、中国圣牧、现代牧业、西部牧业、和路雪、梦龙、Grom、特仑苏、金典、三元、旺仔、辉山、完达山、维他奶等
2020年1月21日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2019-2020中国乳业行业运行大数据及市场趋势研究报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对中国乳业的发展现状、国际贸易环境和上下游进行深度分析,并且以蒙牛集团、光明乳业、伊利集团、飞鹤乳业等上市公司作为典型案例进行商情分析,深入研究中国乳业行业运行模式和发展趋势。2019年10月,全国监测城市鲜奶平均零售价格每斤为5.40元,环比涨0.4%,同比涨1.9%。其中,袋装鲜奶每斤4.96元,环比涨0.4%,同比涨1.6%。盒装鲜奶每斤5.84元,环比涨0.3%,同比涨2.1%。艾媒咨询分析师认为,随着对鲜奶的认识越发深入,消费者对鲜奶的需求量不断扩大,中国鲜奶市场将持续增长,预计到2020年鲜奶零售价将保持稳步增长的趋势。
The report conducts an in-depth analysis of the development status, international trade environment, and upstream and downstream of China's dairy industry. Group companies, Feihe Dairy and other listed companies conduct business analysis as typical cases, and in-depth study of the operation mode and development trend of China's dairy industry. In October 2019, the average retail price of fresh milk in monitored cities nationwide was 5.40 yuan per catty, up 0.4% month-on-month and 1.9% year-on-year. Among them, bagged fresh milk was 4.96 yuan per catty, up 0.4% month-on-month and 1.6% year-on-year. Boxed fresh milk was 5.84 yuan per catty, up 0.3% month-on-month and 2.1% year-on-year. iiMedia Research Consulting analysts believe that as the understanding of fresh milk deepens and consumer demand for fresh milk continues to expand, the Chinese fresh milk market will continue to grow, and it is expected that the retail price of fresh milk will maintain a steady growth trend by 2020 . -
艾媒报告|2020-2021中国 MCN产业运行大数据监测及趋势研究报告
本报告研究涉及企业/品牌/案例:星期六,极米传媒科技,天龙集团,引力传媒,日出东方,元隆雅图,国旅联合,美盛文化,网达软件,粤传媒,中广天择,黑芝麻,中昌数据,拉芳家化,日播时尚,天创时尚,芒果超媒,安奈儿,南极电商,电声股份,搜于特,沉浸文化,大鹅文化,婉锐(上海)电子商务,网星梦工厂,杭州微念科技,灰斑马,彦祖文化,小象互娱,五月美妆,泰洋川禾,光风霁月,papitube,薇娅,李佳琦,李子柒,办公室小野,张大奕,毒角SHOW,吴佳煜,幸猴儿,留几手,张雪峰老师,Papi酱,祝晓晗,花一村,快递员吴彦祖,米未传媒,微博,微信,今日头条,抖音,网易,火山小视频,西瓜视频,快手,易车,汽车之家,bilibili,马蜂窝,小红书,京东,淘宝,蘑菇街,楼氏传播,蜂群传媒,陌陌,爱奇艺,虎牙直播,斗鱼直播,大禹,青藤文化,二更,新片场,三感 video,罐头视频,小题影视,洋葱视频,末那传媒,橘子娱乐,飞博共创,杭州宸帆,如涵控股,美嗖文化,达人说,美 ONE,军武科技,有狐文化,鹿角熊,无忧传媒,星匠联盟,贝壳视频,灵魂有香气的女子,日日煮,十二栋文化,震惊文化,吾皇的白茶,幕星社,Drama TV,YouTube等
2020年1月22日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020-2021年中国MCN产业运行大数据监测及趋势研究报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对中国MCN产业的发展现状、产业链细分领域以及MCN业态细分领域进行深度分析,并且以如涵控股、美ONE等具有影响力的MCN公司作为典型进行商情分析,深入探究运行模式和发展趋势。2018年有59.3%的MCN完成过融资,其中半数以上融资轮次集中在A轮(28.6%)和天使轮(23.8%),行业融资类型以早期轮次为主,MCN商业模式仍处于成长期。艾媒咨询分析师认为,MCN机构商业变现形式单一、红人孵化机制不成熟、内容同质化、行业版权保护意识薄弱、负面舆情多等成为中国MCN产业发展面临的主要难题与挑战。未来,中国MCN将要进一步加强行业监管力度、融入互联网行业新兴技术、继续深耕内容垂直行业,同时积极开拓国外市场。
On January 22, 2020, iiMedia Research, a world-renowned third-party data mining and analysis agency for the new economy industry, released the“Research Report on Big Data Monitoring and Trends of China's MCN Industry Operation 2020-2021”.In 2018, 59.3% of MCNs completed financing, of which more than half of the financing rounds were concentrated in round A (28.6%) and angel rounds (23.8%). The type of industry financing was mainly in early rounds, and the MCN business model is still in its growth stage . Ai Media Consulting analysts believe that the single form of commercial realization of MCN institutions, the immature incubation mechanism of reds, the homogeneity of content, the weak awareness of copyright protection in the industry, and the negative public opinion have become the main problems and challenges facing the development of China's MCN industry. In the future, China's MCN will further strengthen industry supervision, integrate emerging technologies in the Internet industry, continue to cultivate vertical content industries, and actively explore foreign markets. -
艾媒报告|2019年12月-2020年1月中国医疗器械行业运行及上市公司双月度报告
本报告研究涉及企业/品牌包括:Mavidon,Titan Medical,Aspire Capital Fund,CentriMag,汇桥资本集团,联影医疗技术集团,医达极星,大博医疗,安捷伦,润扬医疗器械,迈瑞医疗,乐普医疗,威高医用,华大基因,安图生物,健帆生物,鱼跃医疗,京东方科技,美亚光电,东软集团,祥生医疗,硕世生物,佰仁医疗,爱博诺德,伟思医疗,安必平,林华医疗,拱东医疗,天智航,三友医疗,赛科希德等。
截至 2020 年 1 月 31 日 24:00,国家卫生健康委员会公布全国确诊病例 11791 例,重症病例 1795 例。短期来看,预计疫情将继续持续一段时间。肺炎疫情期间,病毒检测带动试剂盒需求增加;病毒治疗带动医用设备及医用耗材需求增加。部分医疗器械企业有望构成业绩增厚。
As of 24:00 on January 31, 2020, the National Health Commission announced 11791 confirmed cases and 1795 severe cases. In the short term, the outbreak is expected to continue for some time. During the pneumonia epidemic, virus detection drives demand for kits; virus treatment drives demand for medical equipment and supplies. Some medical device companies are expected to increase their performance. -
艾媒报告 |2018-2019中国智能手机品牌东南亚市场研究报告
本报告研究涉及企业/品牌包括:三星、苹果、华为、小米、OPPO、中国电信、中国移动、中国联通、中兴、阿里巴巴集团、腾讯、vivo、荣耀、魅族、酷派、360手机、安卓系统、iOS系统、手机管家、商汤、科大讯飞、泰迪熊移动、索尼、夏普、金立、中兴、联想、锤子
随着中国智能手机市场用户红利接近尾声,市场趋于饱和,中国智能手机品牌逐渐将竞争的主战场向海外转移,纷纷走上“出海”战略,而东南亚的巨大潜力使得其成为各个智能手机品牌的主要发力点。iiMedia Research(艾媒咨询)数据显示,2018年小米市场份额荣登印度榜首,在印尼市场,小米、vivo份额大幅增长,OPPO在泰国市场强势扩张。未来,东南亚市场各个智能手机品牌竞争将进一步加剧,品牌高调、渠道下沉将成为主要竞争手段。除此之外,智能手机品牌在重点投入4G的同时将积极应对5G变革。
As the user bonus of Chinese smart phone market comes to an end and the market tends to be saturated, Chinese smart phone brands gradually shift the main battlefield of competition to overseas and embark on the strategy of “going to sea“ one after another. The huge potential of southeast Asia makes it the main starting point for all smart phone brands. According to data from iiMedia Research, xiaomi topped the list in India in market share in 2018. In Indonesia, xiaomi and vivo saw their market share increase significantly, while OPPO expanded strongly in Thailand. In the future, the competition among various smart phone brands in the southeast Asian market will be further intensified, and high-profile brands and sinking channels will become the main means of competition. In addition, smart phone brands will actively respond to 5G revolution while focusing on 4G investment. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry. -
艾媒报告 |2017-2018中国智能手机市场研究报告
本报告研究涉及企业/品牌包括:OPPO、vivo、小米、苹果、华为、三星、荣耀、魅族、酷派、360手机、安卓系统、iOS系统、手机管家、中国移动、中国联通、中国电信、商汤、科大讯飞、泰迪熊移动、索尼、夏普、金立、中兴、联想、锤子
iiMedia Research(艾媒咨询)数据显示, 2017年中国智能手机市场由中国手机厂商引领,华为以20.9%的销量占比成为中国智能手机销售量最高的厂商,OPPO、vivo紧跟其后。小米手机在2017年实现逆势增长,市场销量占比12.9%,超过苹果手机,在中国智能手机销量占比中排名第四。2017年中国手机厂商普遍注重线下渠道,三四线城市竞争日益激烈。
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告